Keeping you up to date on recent developments in cardiology, including: Mutation could hint at heart disease therapeutic target; Nanoparticle system captures heart-disease biomarker; Helping predict chest pain in those with heart disease.
HONG KONG – A Chinese med-tech company plans to take to market what it claims is the first electrocardiography (ECG) diagnostic machine powered by AI, but as it moves to markets beyond China, it could face significant competition.
Startup Conformal Medical Inc. has reeled in $85 million in a series C round to support a U.S. pivotal trial of its CLAAS technology, a device designed to seal off the heart’s left atrial appendage (LAA) to reduce the risk of stroke in patients with atrial fibrillation. The financing included participation from new investors Fidelity Management & Research Company LLC and an undisclosed strategic investor.
Despite the ongoing pandemic, Acutus Medical Inc. (NASDAQ:AFIB) decided to go down the IPO route. It officially started trading today after reporting its offering of more than 8.8 million shares of its common stock at $18 per share, with expected gross proceeds of $158.8 million. Last month, the Carlsbad, Calif.-based company estimated that the IPO price per share would be between $16 and $18.
A promising but side effect-ridden phase III study by Novartis AG with oral imatinib in pulmonary arterial hypertension (PAH) led Boston-based Aerovate Therapeutics Inc. to start exploring two years ago an aerosol form of the kinase inhibitor, and the project has won backing to the tune of $72.6 million in series A money.
Eko Devices Inc. said Tuesday that it is collaborating with British pharma giant Astrazeneca plc to speed the development of digital health tools to improve early detection of cardiovascular diseases, including heart failure. The partnership could lead to more personalized care for heart failure patients, improving long-term outcomes.
Keeping you up to date on recent developments in cardiology, including: Genetic variants contribute to heightened death risk from stroke in those of African descent; Pathologists publish report on likely MIS involving the heart; Studying COVID-19’s impact on the heart.
A medical device company has partnered with a couple of investment firms to tap new technologies and help bring them back to China. Venus Medtech (Hangzhou) Inc. formed a health care investment platform, Ascendum Capital Partners, to invest in new medical devices and technologies around the world, particularly in the cardiovascular and lung disease spaces.
Sudden cardiac arrest (SCA) kills millions of people worldwide each year, triggered by an electrical malfunction in the heart that causes it to unexpectedly stop beating, often without warning. Health care startup Transformative AI Ltd. wants to reduce those deaths. To that end, the company has secured $1.7 million in seed funding for artificial intelligence (AI)-driven software that predicts a patient’s risk of suffering SCA based on subtle physiological changes.